Diatrizoate meglumine / diatrizoate + Linagliptin-metformin

MediHelp rates the interaction as major. Diatrizoate meglumine / diatrizoate and Linagliptin-metformin can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Iodinated contrast can cause acute kidney injury, which impairs metformin elimination. This raises the risk of metformin-associated lactic acidosis, particularly in patients with reduced eGFR or intra-arterial administration.

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Hold metformin at the time of or before the procedure in patients with eGFR below 30 or with acute kidney injury or intra-arterial contrast. Recheck renal function about 48 hours later before restarting.

MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.